DaVita is actively evaluating new treatment technologies like hemodiafiltration (HDF) and expanded hemodialysis using medium cut-off dialyzers.
Filing excerpt
Recent studies relating to removing middle molecule toxins from the blood show promise of improved clinical outcomes, and there are currently two treatment pathways for achieving improved middle molecule clearance.
What this signalsFilings often name leadership changes, deals and spending plans.
Technologies
Regions named
sec-10kproductLaunchGet every 10-K signal for DaVita and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at DaVita this week?”
The Signal API returns 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/4020a988-f104-474f-9993-6670bbc46312 returns this record as JSON. POST /v1/companies/enrich returns every signal for davita.com.
{
"signal_id": "4020a988-f104-474f-9993-6670bbc46312",
"signal_type": "sec-10k",
"signal_subtype": "productLaunch",
"detected_at": "2026-02-17T06:37:53.052+00:00",
"company": {
"name": "DaVita",
"domain": "davita.com"
},
"data": {
"detail": "DaVita is actively evaluating new treatment technologies like hemodiafiltration (HDF) and expanded hemodialysis using medium cut-off dialyzers. This creates an opportunity for medical device manufacturers and suppliers of related equipment and consumables to engage with their clinical and procurement teams.",
"metrics": {
"timeframe": "current_year"
},
"summary": "Evaluating new dialysis modalities including hemodiafiltration (HDF) to improve outcomes",
"excerpts": "Recent studies relating to removing middle molecule toxins from the blood show promise of improved clinical outcomes, and there are currently two treatment pathways for achieving improved middle molecule clearance.",
"relevance": 0.7,
"sentiment": "neutral",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/927066/000092706626000012/dva-20251231.htm",
"filing_date": "2026-02-11",
"filing_year": 2026,
"fiscal_year_end": "12/31",
"sales_relevance": "Go-to-market support",
"signal_category": "strategic",
"regions_mentioned": [
"U.S."
],
"technologies_mentioned": [
"hemodiafiltration (HDF)",
"expanded hemodialysis"
]
}
}
curl https://signals.autobound.ai/v1/signals/4020a988-f104-474f-9993-6670bbc46312 \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"davita.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.